- Home
- TILE vs PVLA Comparison
TILE vs PVLA Comparison
Compare TILE & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TILE | PVLA |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | TILE | PVLA |
|---|---|---|
| Price | $27.78 | $122.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $36.00 | ★ $161.13 |
| AVG Volume (30 Days) | ★ 410.3K | 314.8K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,386,854,000.00 | N/A |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $17.31 | $18.23 |
| 52 Week High | $35.11 | $151.18 |
Technical Indicators
Market Signals| Indicator | TILE | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 28.97 | 54.75 |
| Support Level | $27.55 | $76.95 |
| Resistance Level | $28.87 | $151.18 |
| Average True Range (ATR) | 0.99 | 10.39 |
| MACD | -0.37 | -0.09 |
| Stochastic Oscillator | 15.50 | 34.50 |
Price Performance
Historical ComparisonAbout TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.